Literature DB >> 33563664

Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression.

Daniele Tavernari1,2,3, Elena Battistello1,2,3,4, Elie Dheilly1,4, Aaron S Petruzzella1,4, Marco Mina1,2,3, Jessica Sordet-Dessimoz4, Solange Peters1,5, Thorsten Krueger6, David Gfeller1,7, Nicolo Riggi1,8, Elisa Oricchio1,4, Igor Letovanec9,8,10, Giovanni Ciriello9,2,3.   

Abstract

Cancer evolution determines molecular and morphologic intratumor heterogeneity and challenges the design of effective treatments. In lung adenocarcinoma, disease progression and prognosis are associated with the appearance of morphologically diverse tumor regions, termed histologic patterns. However, the link between molecular and histologic features remains elusive. Here, we generated multiomics and spatially resolved molecular profiles of histologic patterns from primary lung adenocarcinoma, which we integrated with molecular data from >2,000 patients. The transition from indolent to aggressive patterns was not driven by genetic alterations but by epigenetic and transcriptional reprogramming reshaping cancer cell identity. A signature quantifying this transition was an independent predictor of patient prognosis in multiple human cohorts. Within individual tumors, highly multiplexed protein spatial profiling revealed coexistence of immune desert, inflamed, and excluded regions, which matched histologic pattern composition. Our results provide a detailed molecular map of lung adenocarcinoma intratumor spatial heterogeneity, tracing nongenetic routes of cancer evolution. SIGNIFICANCE: Lung adenocarcinomas are classified based on histologic pattern prevalence. However, individual tumors exhibit multiple patterns with unknown molecular features. We characterized nongenetic mechanisms underlying intratumor patterns and molecular markers predicting patient prognosis. Intratumor patterns determined diverse immune microenvironments, warranting their study in the context of current immunotherapies.This article is highlighted in the In This Issue feature, p. 1307. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33563664     DOI: 10.1158/2159-8290.CD-20-1274

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  13 in total

1.  FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma.

Authors:  Grace Orstad; Gabriela Fort; Timothy J Parnell; Alex Jones; Chris Stubben; Brian Lohman; Katherine L Gillis; Walter Orellana; Rushmeen Tariq; Olaf Klingbeil; Klaus Kaestner; Christopher R Vakoc; Benjamin T Spike; Eric L Snyder
Journal:  Dev Cell       Date:  2022-07-13       Impact factor: 13.417

Review 2.  Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.

Authors:  Jae Young So; Joyce Ohm; Stan Lipkowitz; Li Yang
Journal:  Pharmacol Ther       Date:  2022-07-21       Impact factor: 13.400

3.  Circular RNAs Hsa_circ_101555 and Hsa_circ_008068 as Diagnostic Biomarkers for Early-Stage Lung Adenocarcinoma.

Authors:  Xue Lian; Dakui Cao; Xun Hu; Weiqiang Mo; Xiujuan Yao; Juanfen Mo; Haiqin Wang
Journal:  Int J Gen Med       Date:  2022-06-09

4.  Analysis of the Single-Cell Heterogeneity of Adenocarcinoma Cell Lines and the Investigation of Intratumor Heterogeneity Reveals the Expression of Transmembrane Protein 45A (TMEM45A) in Lung Adenocarcinoma Cancer Patients.

Authors:  Patrícia Neuperger; József Á Balog; László Tiszlavicz; József Furák; Nikolett Gémes; Edit Kotogány; Klára Szalontai; László G Puskás; Gábor J Szebeni
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

5.  HyperChIP: identification of hypervariable signals across ChIP-seq or ATAC-seq samples.

Authors:  Haojie Chen; Shiqi Tu; Chongze Yuan; Feng Tian; Yijing Zhang; Yihua Sun; Zhen Shao
Journal:  Genome Biol       Date:  2022-02-28       Impact factor: 13.583

Review 6.  Heterogeneity of the tumor immune microenvironment and its clinical relevance.

Authors:  Qingzhu Jia; Aoyun Wang; Yixiao Yuan; Bo Zhu; Haixia Long
Journal:  Exp Hematol Oncol       Date:  2022-04-23

7.  Transcriptional patterns reveal tumor histologic heterogeneity and immunotherapy response in lung adenocarcinoma.

Authors:  Mengxue Jiao; Hui Liu; Xuejun Liu
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

8.  Age does matter in adolescents and young adults vs. older adults with lung adenocarcinoma: A retrospective analysis comparing clinical characteristics and outcomes in response to systematic treatments.

Authors:  Lin Zhou; Huiwu Li; Shuhui Yang
Journal:  Oncol Lett       Date:  2022-08-31       Impact factor: 3.111

Review 9.  Deciphering the Immune-Tumor Interplay During Early-Stage Lung Cancer Development via Single-Cell Technology.

Authors:  Wei-Wei Chen; Wei Liu; Yingze Li; Jun Wang; Yijiu Ren; Guangsuo Wang; Chang Chen; Hanjie Li
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

10.  Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler.

Authors:  Helga Bergholtz; Jodi M Carter; Alessandra Cesano; Maggie Chon U Cheang; Sarah E Church; Prajan Divakar; Christopher A Fuhrman; Shom Goel; Jingjing Gong; Jennifer L Guerriero; Margaret L Hoang; E Shelley Hwang; Hellen Kuasne; Jinho Lee; Yan Liang; Elizabeth A Mittendorf; Jessica Perez; Aleix Prat; Lajos Pusztai; Jason W Reeves; Yasser Riazalhosseini; Jennifer K Richer; Özgür Sahin; Hiromi Sato; Ilana Schlam; Therese Sørlie; Daniel G Stover; Sandra M Swain; Alexander Swarbrick; E Aubrey Thompson; Sara M Tolaney; Sarah E Warren
Journal:  Cancers (Basel)       Date:  2021-09-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.